Synlogic is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases in need of new treatment options. The Company focuses on rare metabolic diseases, with its lead program, labafenogene marselecobac (SYNB1934), currently being studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for classical homocystinuria (HCU). Both PKU and HCU are caused by inborn errors of metabolism, and present significant need for innovation due to limitations of today’s medical treatment options.

Synlogic’s early-stage pipeline includes research and development on product candidates addressing medical needs in enteric hyperoxaluria, gout, cystinuria, as well as inflammatory bowel disease (IBD).  The Company’s productivity is fueled by a reproducible, proprietary approach that creates new enzymatic pathways designed to consume or produce specific biological targets provided in GI-restricted, orally administered biopharmaceuticals.  Synlogic designs, develops and manufactures these drug candidates, which are produced by applying precision genetic engineering to well-characterized probiotics.  For more information, please visit www.synlogictx.com or follow us on Twitter, Facebook, Instagram, and YouTube.